$-0.18 EPS Expected for Capricor Therapeutics (CAPR); Last Week Mattioli Woods plc (LON:MTW) Coverage

July 18, 2017 - By marketbeat

Analysts expect Capricor Therapeutics Inc (NASDAQ:CAPR) to report $-0.18 EPS on August, 21.They anticipate $0.08 EPS change or 30.77% from last quarter’s $-0.26 EPS. After having $-0.17 EPS previously, Capricor Therapeutics Inc’s analysts see 5.88% EPS growth. About 223,907 shares traded or 103.22% up from the average. Capricor Therapeutics Inc (NASDAQ:CAPR) has declined 72.31% since July 18, 2016 and is downtrending. It has underperformed by 89.01% the S&P500.

Among 6 analysts covering Mattioli Woods PLC (LON:MTW), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Mattioli Woods PLC had 33 analyst reports since August 17, 2015 according to SRatingsIntel. Shore Capital maintained the shares of MTW in report on Monday, January 9 with “Hold” rating. Shore Capital maintained the shares of MTW in report on Tuesday, February 7 with “Hold” rating. The rating was maintained by Canaccord Genuity with “Hold” on Thursday, September 22. The rating was maintained by FinnCap with “Hold” on Thursday, September 8. On Wednesday, September 9 the stock rating was downgraded by Canaccord Genuity to “Hold”. As per Tuesday, February 16, the company rating was upgraded by N+1 Singer. The rating was upgraded by FinnCap to “Buy” on Tuesday, February 7. The company was maintained on Wednesday, May 18 by Macquarie Research. Canaccord Genuity maintained it with “Hold” rating and GBX 570 target in Monday, October 5 report. The firm has “Hold” rating given on Monday, January 9 by FinnCap. See Mattioli Woods plc (LON:MTW) latest ratings:

05/07/2017 Broker: Shore Capital Rating: Hold Maintain
05/07/2017 Broker: FinnCap Rating: Buy Old Target: GBX 850.00 New Target: GBX 850.00 Maintain
15/02/2017 Broker: Canaccord Genuity Rating: Hold Old Target: GBX 735.00 New Target: GBX 795.00 Reiteration
14/02/2017 Broker: Macquarie Research Rating: Neutral Old Target: GBX 735.00 New Target: GBX 735.00 Maintain
07/02/2017 Broker: Shore Capital Rating: Hold Maintain
07/02/2017 Broker: FinnCap Rating: Buy New Target: GBX 850.00 Upgrade

About shares traded. Mattioli Woods plc (LON:MTW) has 0.00% since July 18, 2016 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 0.88 in Q4 2016. Its up 0.05, from 0.83 in 2016Q3. It improved, as 34 investors sold Mattioli Woods plc shares while 55 reduced holdings. 33 funds opened positions while 45 raised stakes. 100.53 million shares or 0.04% more from 100.49 million shares in 2016Q3 were reported. Cwm Ltd Com owns 0% invested in Mattioli Woods plc (LON:MTW) for 3,091 shares. Clearbridge Invs Lc has 373,697 shares. Weiss Asset Mgmt Ltd Partnership reported 31,013 shares or 0.03% of all its holdings. Qci Asset Mgmt Ny invested in 1,500 shares. Sg Americas Secs Ltd Com owns 37,747 shares or 0% of their US portfolio. State Of Wisconsin Investment Board has 0.01% invested in Mattioli Woods plc (LON:MTW) for 394,613 shares. Jfs Wealth Advsrs Ltd Com owns 58 shares. California Pub Employees Retirement reported 261,500 shares. Alliancebernstein Lp invested in 204,920 shares. Joel Isaacson Com Lc has 786 shares for 0% of their portfolio. Millennium Mgmt holds 0.01% or 643,385 shares in its portfolio. 16,059 are owned by Amalgamated Bank. Nationwide Fund Advsr holds 0% of its portfolio in Mattioli Woods plc (LON:MTW) for 102,601 shares. Aqr Mngmt Ltd owns 142,527 shares. Birmingham Capital Mgmt Incorporated Al reported 0.06% of its portfolio in Mattioli Woods plc (LON:MTW).

Since February 15, 2017, it had 1 buy, and 6 selling transactions for $266,860 activity. Ravenscroft Aaron H. bought $32,834 worth of stock or 5,000 shares. MUSIAL THOMAS G also sold $37,138 worth of Mattioli Woods plc (LON:MTW) on Tuesday, February 21. Shares for $17,999 were sold by Weyers Lawrence Joseph. Shares for $6,064 were sold by Raymond Louis F. on Tuesday, February 21.

Mattioli Woods plc is engaged in providing pensions consultancy and administration services primarily to owner-managers, senior executives and professional persons in the United Kingdom. The company has market cap of 205.02 million GBP. It offers a range of services namely wealth management, employee benefits and intermediary services. It has a 37.85 P/E ratio. Wealth management services include: financial planning, which provide wealth building and trust planning; investments, which include portfolio management, structured products and individual savings account ; pension, which provide self-invested personnel pension and small Self-Administered Scheme(SSAS); property, which includes real estate investment trust (REIT), mortgage advice and legal services, and Protection, which includes life insurance and income protection.

Since May 9, 2017, it had 3 buys, and 0 insider sales for $3.66 million activity. Manzo Louis also bought $31,000 worth of Capricor Therapeutics Inc (NASDAQ:CAPR) shares. On Tuesday, May 9 the insider Musket David B bought $77,500. 1.15 million shares were bought by CEDARS SINAI MEDICAL CENTER, worth $3.55M on Tuesday, May 9.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm focused on the discovery, development and commercialization of therapeutics. The company has market cap of $24.35 million. The Firm focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. It currently has negative earnings. The Company’s product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction , while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.